Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-22
DOI
10.1111/1759-7714.14156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- (2021) Jiali Yu et al. NATURE MEDICINE
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
- (2021) Shu-Yan He et al. World Journal of Clinical Cases
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
- (2020) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
- (2020) Xiang Long et al. OncoTargets and Therapy
- Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
- (2020) Antonio Passaro et al. Journal of Thoracic Oncology
- Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
- (2019) Shouzheng Wang et al. Thoracic Cancer
- Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
- (2019) Sheng-Kai Liang et al. LUNG CANCER
- Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
- (2019) Tianli Zhang et al. Translational Lung Cancer Research
- Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
- (2019) Peter T Harrison et al. SEMINARS IN CANCER BIOLOGY
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
- (2019) Ashiq Masood et al. SEMINARS IN ONCOLOGY
- Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
- (2019) Ana C.Z. Gelatti et al. LUNG CANCER
- Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
- (2019) Lei Lei et al. Cancer Medicine
- Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non–Small-Cell Lung Cancer With Liver Metastases
- (2019) William B. Wong et al. Journal of Oncology Practice
- Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
- (2019) Lei Lei et al. CANCER SCIENCE
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation
- (2018) Atsushi Osoegawa et al. INVESTIGATIONAL NEW DRUGS
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib
- (2018) You-Cai Zhu et al. Journal of Thoracic Disease
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset
- (2018) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
- (2018) Bao-Dong Qin et al. OncoTargets and Therapy
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
- (2017) Hai-Yan Tu et al. LUNG CANCER
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
- (2017) Shinji Kohsaka et al. Science Translational Medicine
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
- (2016) Martin Schuler et al. Journal of Thoracic Oncology
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
- (2015) J.-N. Gallant et al. Cancer Discovery
- Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
- (2014) Satoshi Watanabe et al. Journal of Thoracic Oncology
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
- (2013) Erminia Massarelli et al. LUNG CANCER
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
- (2012) Susumu Kobayashi et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search